The cost of maternal cocaine abuse: I. Perinatal cost.
Although the clinical impact of maternal cocaine abuse has been well documented in recent years, there have been no reports on the direct and indirect costs of such abuse. This study compares hospital charges of a cocaine-abusing population with those of a control group. Ninety-one mother-infant pairs testing positive for cocaine at delivery were compared with a screened drug-free control population matched for socioeconomic status, age, and parity. When compared with controls, cocaine-positive mothers were more likely to deliver prematurely (37 versus 2%) and to have low birth weight (2613 versus 3340 g) or growth-retarded infants (12 versus 0%) with Apgar scores less than 7 at 5 minutes (8 versus 1%), signs of cocaine exposure (63 versus 0%), neonatal intensive care use (30 versus 3%), and extensive hospitalization (11 versus 3 days). As expected, there was a substantial cost difference between the study and control groups. Hospital charges for the labor, delivery, and postpartum care of cocaine-positive mothers in the study group averaged $3608, whereas maternal control charges averaged $3147 (P less than .05). Neonatal charges from the cocaine-positive study group averaged $13,222, whereas control charges averaged only $1297 (P less than .03). Most of the statistically significant differences in perinatal cost between the cocaine-positive and control populations can be traced to the association between cocaine abuse and premature birth. This information should benefit institutions and organizations trying to assess cost-benefit aspects of programs for prevention and treatment of cocaine abuse during pregnancy.
Department of Obstetrics and Gynecology, Oregon Health Sciences University, Emanuel Hospital and Health Center, Portland.
B C
BC
Calhoun
P T
PT
Watson
D000328:Adult; D016022:Case-Control Studies; D003042:Cocaine / Q000009:adverse effects*; D003365:Costs and Cost Analysis; D005260:Female; D005317:Fetal Growth Retardation / Q000191:economics / Q000628:therapy; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000191:economics / Q000628:therapy; D015931:Intensive Care, Neonatal / Q000191:economics; D007902:Length of Stay / Q000191:economics; D009357:Neonatal Abstinence Syndrome / Q000191:economics* / Q000628:therapy; D011247:Pregnancy; D011248:Pregnancy Complications / Q000191:economics*; D011256:Pregnancy Outcome / Q000191:economics; D011295:Prenatal Care; D012907:Smoking / Q000009:adverse effects; D019966:Substance-Related Disorders / Q000191:economics*
D003042:Cocaine